Skip to main content
. 2012 Mar 16;6(4):467–470. doi: 10.1007/s12105-012-0351-x

Table 1.

Clone, dilution, and manufacturer of primary antibodies used in the present case

Antibody Clone Dilution Manufacturer
Vimentin V9 1:100 DAKO
Neuron-specific enolase BBS/NC/VI-H14 1:150 DAKO
Pan-keratin AE1/AE3 1:50 DAKO
S-100 protein 4C4.9 1:200 ZYTOMEDa
Carcinoembryonic antigen (CEA) A0115 1:40 DAKO
Glial fibrilliary acidic protein (GFAP) 6F2 1:100 DAKO
Alpha smooth muscle actin NCL-SMA 1:50 NOVOCASTRAb
Muscle specific actin HHF35 Ready to use DAKO
Desmin D33 1:100 DAKO
CD68 KP-1 1:100 DAKO
CD31 JC70A 1:40 DAKO

aZytomed Systems GmbH, Berlin, Germany

bNovocastra™, Leica Biosystems Newcastle Ltd, Newcastle Upon Tyne, UK